No Data
No Data
Trevi Therapeutics Shares Are Trading Higher After the Company Announced Positive Outcomes for the Treatment of Patients From Its Chronic Cough Phase 2b CORAL Trial.
Sector Update: Health Care
Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.
Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Trevi Therapeutics Phase IIb Update a Major De-risking Event, Says B. Riley
H.C. Wainwright Ups Trevi Therapeutics Target After 'Best-case' for CORAL
Trytosaveabit : Nope because they have market makers on their side! And they can use shares that don’t even exist! Hehehe! s